Tag: myelofibrosis

December 28, 2018 Off

CTI BioPharma prepares myelofibrosis patients for second phase testing of pacritinib

CTI BioPharma has enrolled 150 patients with myelofibrosis previously treated with ruxolitinibto be tested on pacritinib in the second phase, testing three dosing schedules over 24 weeks.

July 13, 2017 Off

CTI BioPharma’s myelofibrosis drug one step closer to EMA’s approval

By Dino Mustafić

European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for CTI BioPharma’s pacritinib for the treatment of patients with myelofibrosis who have thrombocytopenia.